Fig 1.
Flowchart illustrating eligible patients after inclusion and exclusion criterion. The final study population consisted of 6,796 patients. CABG = coronary artery by-pass graft surgery; D1 = first diagonal branch; DES = drug-eluting stent; LAD = left anterior descending; LM = left main; PCI = percutaneous coronary intervention.
Table 1.
Baseline characteristics. ACEi = angiotensin-converting-enzyme inhibitor; ARB = angiotensin II receptor blocker; ASA = acetylsalicylic acid; CAD = coronary artery disease; NSTEMI = non-ST-elevation myocardial infarction; PCI = percutaneous coronary intervention; STEMI = ST-elevation myocardial infarction.
Table 2.
Outcomes. *Adjusted for: age, sex, inclusion year, diabetes mellitus, hypertension, hyperlipidemia, smoking status (non-smokers, previous smokers and active smokers), use of intracoronary imaging, indication (stable coronary artery disease, unstable angina, NSTEMI and STEMI) and lesion classification (B1 bifurcation, B2 bifurcation and C bifurcation).
Fig 2.
Kaplan-Meier curves illustrating the 5-year event rate of (A) major adverse clinical events, (B) all-cause mortality, (C) myocardial infarction, (D) target segment revascularization or CABG, (E) definite stent thrombosis, (F) bleeding event, and (G) stroke. Major adverse cardiovascular event was defined as all-cause mortality or myocardial infarction. CABG = coronary artery by-pass graft surgery; PCI = percutaneous coronary intervention.